Treating oesophageal carcinoma involves a combination of approaches tailored to each person’s unique situation, aiming to control symptoms, slow disease progression, and improve quality of life wherever possible.

Finding the Right Path: How Treatment is Chosen

When someone is diagnosed with oesophageal carcinoma, the treatment journey begins with understanding where the disease stands and what the person’s body can handle. The treatment approach depends heavily on several factors: how far the cancer has spread through the layers of the oesophagus, whether it has reached nearby lymph nodes or distant organs, and the person’s overall health and personal preferences.^[1][2]

The two main types of oesophageal cancer—squamous cell carcinoma (which forms in the flat cells lining the oesophagus) and adenocarcinoma (which develops in glandular cells, usually in the lower oesophagus)—may require slightly different treatment strategies. Medical teams typically include surgeons, medical oncologists who specialize in drug treatments, radiation oncologists, and other specialists who work together to create a personalized treatment plan.^[4][5]

Treatment goals vary depending on the stage at diagnosis. For early-stage disease detected before it spreads, the goal may be to eliminate the cancer entirely through surgery and other therapies. For more advanced disease, treatment focuses on controlling growth, relieving symptoms like difficulty swallowing, and helping people maintain their strength and comfort for as long as possible.^[2][10]

Standard Treatment Approaches

Surgery for Oesophageal Cancer

Surgery remains one of the most important treatment options when oesophageal cancer is caught early, before it spreads widely. The main surgical procedure is called an oesophagectomy, which involves removing part or all of the oesophagus along with nearby lymph nodes. Surgeons then reconstruct the digestive tract, typically by pulling up part of the stomach to connect to the remaining oesophagus or to the throat.^[10][13]

Different surgical techniques exist. A transhiatal approach accesses the oesophagus through incisions in the abdomen and neck, while a transthoracic approach requires opening the chest. More recently, minimally invasive robotic surgery has become available at specialized centers, using small incisions and robotic instruments to remove the cancer with potentially less trauma to the body and faster recovery times.^[16][18]

Surgery is a major undertaking with significant effects on the body. After removing part of the oesophagus and reshaping the stomach, people need to adjust to eating smaller, more frequent meals since the stomach’s capacity is reduced. Recovery can take several months, and some changes to eating habits may be permanent.^[13][20]

For very early cancers confined to the inner lining of the oesophagus, less invasive procedures may be possible. Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) use flexible tubes passed down the throat to remove small cancers without major surgery. These techniques work through a camera-guided tube, allowing doctors to cut away cancerous tissue while preserving most of the oesophagus.^[18]

Chemotherapy

Chemotherapy uses drugs that travel through the bloodstream to attack cancer cells throughout the body. For oesophageal cancer, chemotherapy serves multiple roles depending on the stage and treatment plan. It may be given before surgery to shrink tumors, making them easier to remove—this is called neoadjuvant chemotherapy. It can also be given after surgery to kill any remaining cancer cells, known as adjuvant chemotherapy. For advanced disease that cannot be surgically removed, chemotherapy helps control cancer growth and relieve symptoms.^[5][13]

Common chemotherapy drugs for oesophageal cancer include fluoropyrimidines (such as 5-fluorouracil or capecitabine), which interfere with cancer cells’ ability to make DNA; platinum-based drugs (such as cisplatin or oxaliplatin), which damage cancer cell DNA; and taxanes (such as paclitaxel or docetaxel), which prevent cancer cells from dividing properly. These drugs are often used in combinations to increase effectiveness.^[17][18]

Chemotherapy affects both cancer cells and some healthy cells that divide rapidly, leading to side effects. Common side effects include nausea and vomiting, fatigue, loss of appetite, increased risk of infection due to low blood cell counts, hair loss, mouth sores, and numbness or tingling in hands and feet (called neuropathy). Most side effects are temporary and improve after treatment ends, though some like neuropathy may persist.^[13]

The duration of chemotherapy varies. When given before surgery, treatment typically lasts several weeks to a few months. For advanced cancer, chemotherapy may continue as long as it is helping control the disease and side effects remain manageable.^[17]

Radiation Therapy

Radiation therapy uses high-energy beams to damage cancer cell DNA, preventing them from growing and dividing. For oesophageal cancer, external beam radiation is most common, delivered by a machine that aims radiation precisely at the tumor from outside the body. Treatments are typically given five days a week for several weeks.^[10][13]

Radiation is frequently combined with chemotherapy in a treatment called chemoradiation or chemoradiotherapy. The chemotherapy makes cancer cells more sensitive to radiation, increasing effectiveness. This combination may be used before surgery to shrink tumors, or as the main treatment for people who cannot have surgery or whose cancer is in the upper oesophagus near the throat.^[18]

Side effects from radiation to the oesophagus can include difficulty and pain when swallowing due to inflammation of the oesophageal lining, fatigue, skin changes in the treated area, and nausea. When radiation is aimed at the chest, it may also affect the lungs and heart. Most side effects gradually improve after treatment ends, though some people develop long-term scarring or narrowing of the oesophagus that may require additional procedures to stretch it open.^[13]

Targeted Therapy

Targeted therapies are drugs designed to attack specific features of cancer cells while causing less harm to normal cells than traditional chemotherapy. For oesophageal adenocarcinoma, one important targeted therapy is trastuzumab, which works against cancers that have high levels of a protein called HER2 on their surface. This protein helps cancer cells grow and divide; trastuzumab blocks HER2, slowing cancer growth.^[13][18]

Before receiving trastuzumab, patients undergo testing to determine if their cancer cells have elevated HER2 levels—this is an example of companion diagnostics, where a test guides treatment selection. Trastuzumab is given by infusion into a vein, typically every few weeks in combination with chemotherapy for advanced oesophageal adenocarcinoma.^[18]

Another targeted drug used for advanced disease is ramucirumab, which blocks blood vessel growth that tumors need to survive. It is also given by infusion, usually combined with chemotherapy. Side effects of targeted therapies differ from chemotherapy and may include high blood pressure, bleeding, and effects on heart function in the case of trastuzumab.^[17][18]

Immunotherapy

Immunotherapy helps the body’s own immune system recognize and attack cancer cells. Cancer cells sometimes evade the immune system by using proteins that act like “off switches.” Immune checkpoint inhibitors block these proteins, allowing immune cells to attack the cancer.^[2][10]

For oesophageal cancer, nivolumab and pembrolizumab are checkpoint inhibitors that target a protein called PD-1. These drugs are used for advanced oesophageal cancer, either when chemotherapy is no longer working or sometimes as a first treatment in combination with chemotherapy. They are given by infusion into a vein every few weeks.^[13][18]

Immunotherapy has different side effects than chemotherapy because it stimulates the immune system. This can sometimes cause the immune system to attack healthy tissues, leading to inflammation in organs like the lungs, intestines, liver, or hormone-producing glands. Most people tolerate immunotherapy well, but close monitoring is important to catch and treat immune-related side effects early.^[17]

Palliative Treatments for Symptom Relief

For people with advanced oesophageal cancer, treatments focused on relieving symptoms and improving quality of life are crucial. Difficulty swallowing is one of the most distressing symptoms when a tumor blocks the oesophagus. Several procedures can help reopen the passage for food and liquids.^[13][25]

Oesophageal stents are expandable metal or plastic tubes inserted through an endoscope (a flexible viewing tube) to hold open the narrowed area. This procedure can quickly restore the ability to swallow. Laser therapy and photodynamic therapy use light energy to destroy tumor tissue blocking the oesophagus. Radiofrequency ablation uses heat to remove tumor tissue.^[13][18]

For people who cannot swallow enough to maintain nutrition, a feeding tube may be placed directly into the stomach or small intestine through the abdominal wall. This allows liquid nutrition to be given while bypassing the blocked oesophagus. While this requires adjustment, it helps people maintain strength and quality of life.^[20][25]

Treatment in Clinical Trials

Beyond standard treatments, researchers are constantly testing new approaches in clinical trials—carefully designed studies that evaluate experimental treatments. Participating in a clinical trial can give access to promising new therapies before they become widely available, while also contributing to medical knowledge that helps future patients.^[11]

Understanding Clinical Trial Phases

Clinical trials progress through phases, each with a different purpose. Phase I trials test a new treatment in a small group of people (typically 20-80) to evaluate safety, determine safe dosage ranges, and identify side effects. These are the first tests in humans after laboratory and animal studies. Phase II trials involve larger groups (100-300 people) and focus on whether the treatment works against the cancer while continuing to monitor safety. Phase III trials compare the new treatment to current standard treatments in large groups (1,000-3,000 people) to determine if it is more effective, has fewer side effects, or offers other advantages.^[5]

Innovative Molecules and Therapies Under Investigation

Several exciting approaches are being studied in clinical trials for oesophageal cancer. One area of active research involves newer checkpoint inhibitors and combinations of different immunotherapy drugs. Scientists are testing whether combining checkpoint inhibitors that target different immune pathways might be more effective than using one alone. Studies are also exploring whether giving immunotherapy earlier in treatment—before or alongside chemotherapy and radiation—can improve long-term outcomes.^[11][16]

Another promising direction involves targeted therapies against newly discovered molecular vulnerabilities in oesophageal cancer. Researchers have identified that some oesophageal cancers have alterations in genes controlling cell growth pathways. Drugs targeting these pathways, such as inhibitors of proteins called FGFR (fibroblast growth factor receptor) and EGFR (epidermal growth factor receptor), are being tested. When cancer cells depend on these proteins to grow, blocking them can slow or stop cancer progression.^[11]

Antibody-drug conjugates represent an innovative strategy being explored in trials. These are antibodies—proteins that recognize specific markers on cancer cells—chemically linked to powerful chemotherapy drugs. The antibody acts like a guided missile, delivering chemotherapy directly to cancer cells while sparing healthy tissues. One example being studied is compounds targeting claudin proteins found on oesophageal cancer cells.^[18]

CAR T-Cell Therapy and Cellular Approaches

One of the most innovative areas under investigation involves engineering a patient’s own immune cells to attack cancer. CAR T-cell therapy collects immune cells called T-cells from the patient’s blood, genetically modifies them in a laboratory to recognize cancer cells, then infuses them back into the patient. These modified cells can then multiply and seek out cancer throughout the body. While CAR T-cell therapy has shown remarkable success in some blood cancers, researchers are working to adapt it for solid tumors like oesophageal cancer, which present unique challenges.^[16]

Emerging Results from Clinical Studies

Early results from some Phase II trials testing immunotherapy given after standard chemoradiation and surgery have shown encouraging signs. Studies suggest that continuing checkpoint inhibitors like nivolumab for up to a year after surgery may help prevent cancer recurrence in some patients. These findings led to the therapy being used in selected patients while larger Phase III trials continue to confirm the benefit.^[22]

Trials combining multiple targeted therapies or mixing targeted drugs with immunotherapy are also yielding preliminary positive results in advanced disease, with some studies reporting tumor shrinkage and symptom improvement. However, these remain investigational, and more research is needed to understand which patients benefit most and what the long-term effects might be.^[11]

Accessing Clinical Trials

Clinical trials for oesophageal cancer are conducted at cancer centers and hospitals worldwide, including in the United States, Europe, and other regions. Patients can search for trials through online databases, and many cancer centers have staff dedicated to helping patients understand trial options. Eligibility depends on many factors including cancer stage, genetic characteristics of the tumor, previous treatments received, and overall health status.^[5]

Most Common Treatment Methods

• Surgery
  • Oesophagectomy to remove part or all of the oesophagus along with nearby lymph nodes
  • Minimally invasive robotic surgical techniques for reduced recovery time
  • Endoscopic mucosal resection (EMR) for very early cancers confined to the inner lining
  • Endoscopic submucosal dissection (ESD) to remove small tumors without major surgery
• Chemotherapy
  • Fluoropyrimidines (5-fluorouracil, capecitabine) that interfere with cancer cell DNA production
  • Platinum-based drugs (cisplatin, oxaliplatin) that damage cancer cell DNA
  • Taxanes (paclitaxel, docetaxel) that prevent cancer cell division
  • Given before surgery (neoadjuvant), after surgery (adjuvant), or for advanced disease
• Radiation Therapy
  • External beam radiation delivered precisely to tumor location
  • Often combined with chemotherapy (chemoradiation) for increased effectiveness
  • Used before surgery to shrink tumors or as main treatment when surgery isn’t possible
• Targeted Therapy
  • Trastuzumab for cancers with high HER2 protein levels
  • Ramucirumab that blocks blood vessel growth feeding tumors
  • Drugs targeting specific molecular pathways like FGFR and EGFR (in clinical trials)
• Immunotherapy
  • Checkpoint inhibitors (nivolumab, pembrolizumab) that help immune system attack cancer
  • Used for advanced disease alone or combined with chemotherapy
  • Being studied as adjuvant treatment after surgery in clinical trials
• Palliative Procedures
  • Oesophageal stents to hold open narrowed areas and restore swallowing
  • Laser therapy and photodynamic therapy to destroy blocking tumor tissue
  • Radiofrequency ablation using heat to remove obstructing tumor
  • Feeding tubes for nutrition when swallowing becomes impossible